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Introduction
The power and influence of genetic testing is demonstrated in a case that involved a
three-year-old male with a pregnant mother who came in to a genetic counseling clinic with
symptoms of Mucopolysaccharidosis type II (MPS type II); also known as Hunter’s
syndrome. This disease is caused by a deficiency in the lysosomal enzyme iduronate 2sulfatase which leads to a buildup of glycosaminoglucans in cells all over the body and almost
exclusively affects males. The effect of this is abnormal development during key formative
years and begins to show around ages 2-4. Patient’s exhibit troubled breathing, swelling,
skeletal malformations and neurological degeneration. Most patients with this disease only
live until around age 20 with treatment.1 MPS is an X chromosome linked disease meaning
the mother carries the mutation but, in this case, does not experience symptoms herself
because of her second X chromosome. After diagnosis of the child, the mother was tested and
found to be a carrier of the disease meaning she had a 50% chance of passing on the disease
to her next male child. The mother was in fact thirty-four weeks pregnant at the time of
diagnosis with another male child. The fetus was also tested and found to be affected by the
disease. After deliberation, the parents chose to carry out the pregnancy but gave up the
1
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child for adoption because of the disease and treatment began on both children at the same
clinic. Unexpected findings from genetic testing has a huge impact in the lives of patients.
This is the reality that many patients who undergo genome sequencing face and it is a
problem that researchers of genetics and clinicians alike must address.
Stories like this show the importance and power of genomic data in the lives of
everyday individuals. The mother was made aware of her unborn child’s condition because
of incidental findings that affected her and the child. Next-Generation Sequencing is the
latest and most widely used series of techniques by researchers and clinicians alike to study
heritable diseases like MPS. Genome sequencing allows researchers to narrow down the
problem in the genome which translates into various things down the line like individual
proteins or organ development. Easy genomic testing did not come about until 1977 with the
advent of Sanger sequencing. First generation technologies like this allowed for researchers
to slowly test aspects of a genome. It was not until 2005 with the Genome Analyzer that
allowed for sequencing runs to go from 84 kilobase per run to 1 gigabase per run that easy
genome sequencing was possible. This was the start of the “Next” generation of sequencing.
The first human genome to be sequenced and published was in 2001 and took 15 years and 3
billion dollars to complete. By 2014, the cost for an individual’s genome to be sequenced
dropped to 1000$ and can be done in a single day.2
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Genetic information is becoming more widely used and it has many applications that
go beyond diagnosing a single disease in an individual. Because we have the ability to
analyze the entire set of an individual’s genetic information even though we are looking for
something specific, there is the chance of finding other problems. These other problems that
we find have the ability to severely affect the patient whose genome we are sequencing. For
example, if we found out a patient is likely to experience a deadly heart condition or cancer
in the future while searching for an unknown metabolic disorder. These possible findings are
called secondary findings and are an ever-increasing issue in in the field of genetics.
Secondary findings are findings that concern a patient’s health or are reproductively
significant that are not under the scope of the research being conducted.3 Issues surround the
ability for researchers to fully inform patients as well as addressing the uncertainty of
developing a disease; even with mutated genes. A large part of the discussion is about the
diseases and genes that should be included or not when reporting back to patients with the
final analysis. There is also the issue of calculating the severity of the diseases that should be
included within reports. These are some of the questions that must be addressed when
discussing secondary findings.
I will argue that the best approach for researchers and research institutions when
dealing with secondary findings is to develop an ease of information so that patients are fully
3
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informed going into genetic analysis. The autonomy of the patient is incredibly important
when dealing with requesting secondary findings and in almost all cases, the decision of the
patient is final. Within this thesis, I will be recommending where and how to present
secondary findings to patients and to the Rare Genomics Institute (RG) that works with rare
disease patients from all across the country. I will be recommending genes from the
American College for Medical Genetics secondary findings list as well as my own research to
be included within these secondary findings reports. The goal is to provide a useful and
comprehensive recommendation for RG to start reporting secondary findings to patients so
that they will be even more helpful to patients who contact this non-profit research
institution.
Patients often seek help in a medical clinic, where a clinician communicates with
genetics counseling institutions like RG or guides the patient to contact these institutions
themselves. Patients are then recommended a genetics counselor that helps the patient get
sequenced. After sequencing and initial analysis, the genomic data is sent to these
institutions for further analysis. Institutions like RG pass along the information to registered
volunteers who comb through the data of a patient in order to report back to the institution
which then contacts the patient or the patient’s clinician. This relationship complicates
ethical analysis because volunteers are not medical professionals but are effectively held to a
high standard. Volunteers are given the patient’s exome as well as the immediate family’s
exomes and are the primary data miners. They give their findings to the institute with the

6

recommendation to report or not. In a non-reported case, the results are generally
inconclusive as one or two variants were not deemed to be primarily causative in the patient.
Volunteers use databases like Omicia Opal and OMIM (Online Mendelian Inheritance in
Man database) to analyze the results and reactions of mutations. Omicia comes with analysis
from other databases as well as its own score on the whether a mutation is likely to be
deleterious or not named the Omicia score. This score lies between 0.00 and 1 where the
higher integers indicate likelihood of deleteriousness. Each gene has an Omicia score and the
database allows for sorting via Omicia score and other factors that indicate deleteriousness in
a gene.
Through these indicators, geneticists and volunteers determine the chances of a gene
being causative and report this kind of information. The responsibility of relaying the
findings of the researchers to the patient is the patient advocate or clinician and informed
consent is usually obtained this way as well. Clinicians are often grouped with genetics
researchers in discussions on secondary findings, however they maintain a distinctly separate
role. Clinicians act as a middleman that help patients be informed and sometimes keep
contact with the researching institution. The primary party responsible for the ethical
foundations and work are the researchers who take the genomic information to analyze.
They are the ones responsible for informing the patients and protecting the information
gathered.

7

There is a broad discussion over the significance of secondary findings and whether
researchers are required to report these findings. The general consensus amongst clinicians,
researchers and patients is that these findings should be made available to the patient but
many problems exist between the actors in this ethical quandary.4 From the patient’s
perspective, there is the question of the rights of autonomy that exist between the
information that researchers can provide and future problems that could be mitigated from
this knowledge. Informed consent also creates a situation between patients and researchers
where it is the researcher’s responsibility to fully inform the patient to the best of their
ability, with or without the help of a consulting clinician. There is also the issue of what
researchers would be required to report if they are required to at all. Whole exome
sequencing is limited in its ability to definitely pin a cause to certain diseases as it is only
about 1-2% of the total genome. Recent research has also indicated that the exome is not the
only part of the genome responsible for problems, demonstrating that whole exome
sequencing is limited in some significant ways. The criteria for causative mutations are still
being researched so choosing which genes to report is a tremendous scientific task. Some
institutions like the Rare Genomics Institute, do not currently engage in secondary findings
which effectively rob patients of valuable information that could contemporarily be
presented to them. Through informed consent, respect for autonomy and critical gene
analysis these institutions can effectively provide a means for patients to maximize the
4
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effectiveness and beneficence of genome sequencing. As a primer for the rest of the thesis,
this next chapter is a quick overview of genetics that the reader will need to understand later
chapters.

An Introduction to Genetic Analysis
Hereditary diseases are a result of malfunctions in the complicated machine that is a
human being. DNA (Deoxyribonucleic Acids) is the foundation of this machine and genetics
as a whole. Hidden within DNA is the code that tells the cogs within the machine how to
develop and work; it is the blueprint of the human organism. We knew that DNA was the
blueprint for organisms but the structure of DNA was not discovered until 1953 when James
Watson and Francis Crick published a paper in Nature on the subject with heavy influence
from Rosalind Franklin.5 The blueprints turned out to be only four nucleotides, equivalent to
four letters. The four letter code that makes up DNA was not broken until 1960s when
scientists like Marshall Nirenburg and Johann H. Matteai discovered how information was
stored in these strands.6

“Franklin, Watson &amp; Crick.” 2010.
http://virtuallaboratory.colorado.edu/Biofundamentals/labs/WhatisScience/section_08.html.
6
“Timeline: History of Genomics.” 2016. Wellcome Genome Campus. http://www.yourgenome.org/facts/timelinehistory-of-genomics.
5
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Figure 1: Chimera representation of BDeoxyribonucleic Acid (DNA). The red
and blue strands are the backbone of
the molecule. The central rectangles
represent the four sugars equivalent
to the letters A, T, C, G.

The blueprints are read in triplets, like CAT or TAG, which code for different amino acids.
Amino acids are the next building block which come together to make up proteins. One can
think of proteins as the tiny cogs in the human machine. There is an incredible number of
these cogs within the human machine and the DNA blueprints that buildup everything else
are essentially organized into sections called genes.7 Genes are long sequences of those
triplets which can be tens of thousands of letters long. Genes are divided into two different
sections considered coding and non-coding parts of the gene; like usable and non-usable
parts. Exons are the parts of the gene that remains after certain parts of the transcripted gene
are cut out. Exons are the protein encoding parts of the DNA and are essential in both life
and medical research and the total combination of exons is called the exome. This contrasts
with the genome, in that, the exome is the protein coding parts of the DNA and the genome
is the entire set of DNA; coding and non-coding parts.

7
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The genome is packed into every cell and the genome itself is divided into 23 pairs of
compact DNA called chromosomes. If we are thinking about machines, then chromosomes
can be compared to essential car parts where one chromosome would code for the different
parts of the engine in a car and another would code for the parts that make up the tires.
Chromosomes are more complicated than this in that one chromosome could have parts of
the engine, tires and transmission within it. One missing pair of chromosomes and the car
cannot be completed. All cells have two copies of each chromosome inheriting one from
each parent. The parents produce haploid gametes which are cells that only have one copy of
each chromosome. Each copy of the chromosome inherited from the parents differs slightly.
What people know as traits are the outward expression of the genes on these chromosomes
like the color and form of the car. Traits are known to be recessive or dominant where
recessive traits are those that result of two abnormal alleles being inherited. Dominant traits
are those where only one allele is necessary to exhibit the trait so for example, brown eyes
are more common in the general population because the alleles that encode for brown eyes
are dominant. An allele is a variant form of a gene which is brought about by mutations.
Some mutations are benign and do not change the function of the protein coded by the gene
whereas others are problematic and change or eliminate the function of the protein coded by
the gene. If one copy of a chromosome within an individual has a deleterious mutation, there
is usually another copy with the non-mutated gene that corrects for the mistake. If someone
inherits two of the same allele with the same mutation in both of the inherited
chromosomes, then it is known as homozygous. If someone inherits two different,
11

deleterious mutations then it is known as compound heterozygous. These mutations
sometimes manifest themselves as hereditary disorders and are the motivation for medical
genomic sequencing which brings about the topic issue of secondary findings.
Patterns of inheritance are how genes with mutations in them get passed down onto
the next generation. Autosomal dominant means only one mutated form of the gene needs to
be present to cause the disease whereas two mutated genes need to be present for autosomal
recessive inheritance. X-linked inheritance is affected by dominant and recessive inheritance
but is also the only chromosome that is sex dependent which affects who may experience the
disease. If a male inherits a mutated gene on the X chromosome, they do not have another
copy like females do to correct for the non-functional protein. Somatic mutations are
mutations that occur after conception and multifactorial inheritance means that many factors
play into whether the disease is present or not. Multifactorial inheritance can be a
combination of genetic and environment factors so the disease may not be entirely genetic.
Modern methods of genomic sequencing highlight entire exomes or genomes which
are invaluable to researchers, clinicians and patients.89 New Generation Sequencing (NGS) is
sweeping the market of genomic sequencing leading to lower costs and more availability for

8
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researchers and medical professionals.10 The ability to sequence an entire genome the size of
humans is only a recent development. Frederick Sanger sequenced the first genome of a virus
in 1977 and the first disease associated gene was found in 1983. The Human Genome Project
was launched in 1990 with the goal of sequencing and mapping all the genes within humans
and this goal was completed in 2003.11 This lead to comparable collections of human
genomes like the 1000 Genome Project which researchers use as templates for genetic
study.12 The culmination of sequencing technologies has allowed clinicians and researchers
to analyze a patient’s genome within just a few months. Analyzing a subject’s entire genome
allows genetics professionals to establish the precise causes or influences of certain diseases.
Similarly, whole exome sequencing provides another tool in establishing these causes and is
an easier way to determine causative DNA mutations. There is a vast quantity of data that
genome sequencing creates which researchers and clinicians must sort through which creates
the issue of secondary findings. This takes many forms from pharmacogenetics to genetic
counseling where many fields conduct research using whole genome and exome sequencing.
The problem is two-fold in how we should approach secondary findings and what should we
report to patients. The object of this thesis is to explore and recommend ethical issues
surrounding secondary findings for genetic researchers at the Rare Genomics Institute and to

Morozova, Olena, and Marco A. Marra. “Applications of Next-Generation Sequencing Technologies in
Functional Genomics.” Genomics 92, no. 5 (2008): 255–64. doi:10.1016/j.ygeno.2008.07.001.
11 “All About The Human Genome Project (HGP).” National Human Genome Research Institute, 2015.
https://www.genome.gov/10001772.
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others that provide services to patients with rare genetic diseases; as well as suggest which
genes should be considered in patient reports.
Next Generation Sequencing is expanding the field of genetics at an incredible speed
but at the current time there are still many limitations that we as researchers are bound by
and affect reporting secondary findings. NGS sequencing is still a relatively new technology
so there is a limit on the knowledge that researchers have on the genome and genes
themselves. Not everything is known about some genes like how they function and interact
with other genes. Oftentimes databases will mark mutations in a gene as a “variant of
unknown significance” which is just a mutation whose ramifications are yet unknown to
researchers. Research and scientists are not always correct in their analysis and problems can
develop in reporting secondary findings from simple mistakes. Unknowingly reporting that a
certain mutation within a gene is benign when in reality it has deleterious effects could be a
severe mistake to report to patients. It is not unknown for the significance of a mutation to
change from benign to pathogenic or vice versa. Databases can compound this problem like
Clinvar. Clinvar is a free use database that reports relationships among human variation and
phenotypes with supporting evidence. Clinvar works by integrating multiple other databases
and allows for researchers to report their data. The problems that arise from this aggregation
of sources is that other databases may misreport the pathogenicity of a mutation which then
shows up in Clinvar and pathogenicity reports. Because Clinvar is free it may discourage
researchers from further studying whether a specific mutation is pathogenic or not which

14

could spread misinformation. Databases like Omicia Opal also have problems that stem from
its operations. Omicia is a comprehensive analysis tool for exomes and whole genomes which
show the entire exome and can be compared to others. Omicia uses databases like Clinvar
and COSMIC for its own evaluation of the deleteriousness of gene called the Omicia Score.
Institutes like RG use Omicia Opal for much of their analysis and if other aggregate databases
are wrong about a gene then the misinformation may be given to patients as diagnoses. A lot
of questions surrounding secondary findings stem from these uncertainties but the likelihood
of these database problems is very low and the databases are a great and expediting tool for
genetic analysis that benefits the process of genetic analysis.

Informed Consent
Obtaining permission from the patient is the first incredibly important step when it
comes to analyzing their genomes. Genetic information can be stored indefinitely and can be
reevaluated after new genetic discoveries. Storing genetic data is invaluable for researchers,
clinicians and patients alike and there are many ways organizations are storing this kind of
data. The Personal Genome Project is a research project devoted to sharing genomic data for
these reasons for the benefit of patients and research.13 Patients are also likely to want
discloser of secondary findings or data that is relevant to family members. The genome of
one individual can help warn of risks for both that patient and other members within their
13
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immediate family. There are many possible approaches for patients after they sequence their
genome however it is often an uphill battle in informing patients to an acceptable degree
where they understand what is being asked of and done with their genetic data.
Informed consent is the autonomous and informed authorization by the patient for
participation in research. Clinicians generally have the closest contact with the patients and
their families which, at least on the surface, puts the responsibility of informed consent on
the shoulders of the practitioner clinician. Informed consent is the condition of a patient or
subject having substantial understanding of the process and autonomously authorizes
professionals to work with them.14 As an ethical standard for medicine, informed consent is
necessary when analyzing an individual’s genetic information. Basic moral concepts that
surround the issue of informed consent being; nonmaleficience, beneficience, justice, and
respect for autonomy. The general approach to many medical decisions is being as ethical as
possible when dealing with patients. This approach has been modified from the Hippocratic
Oath and is the general principle of doing no harm15 which is the core of nonmaleficience.
The express goal of clinical work and medical research is to help patients and stop whatever
harm has befallen them. Similarly, the principle of beneficence is the notion that there is an
obligation to act for benefit of others, and in this case patients, and justice is the right to this
treatment.16 The principle of justice is all about the access to healthcare and information.

14
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With this principle, it is important to provide as much information to the patient as possible,
within reason, which is why secondary findings should always be offered. In ignoring
secondary findings, institutions are not doing the patient any justice by robbing them of
valuable information. These are ethics principles that are going to be assumed to be standard
regarding secondary findings.
The importance of informed consent is evident in the problems that have arisen in
the past from unethical medical and research practices. In 1958, a pancreatic enlargement
patient that entered medical care and was recommended by the practitioner to have a
cystoscopic exam. After this exam, the practitioner recommended a transurethral prostatic
resection the next day which makes the patient sterile. The patient was not informed of the
resulting sterilization before the procedure and sued the hospital in the famous Bang vs.
Charles T. Miller Hospital case.1718 This case demonstrates the consequences of a severe
breach in informed consent. In less extreme cases, there is still a difference between
adequately informed and fully informed. This poses a unique problem where a patient should
clearly be fully informed of the medical professional’s intentions but there may be situations
where practitioners and researchers can only adequately inform a patient, especially on
secondary findings. It may be impossible or impractical to fully inform certain patients on
secondary findings with regards to genetics and inheritance probabilities. One piece of
information can influence whether a patient understand the consequences or not. Patient
“Bang v. Charles T. Miller Hospital Case Brief,” 2014. http://www.lawschoolcasebriefs.net/2014/01/bang-vcharles-t-miller-hospital-case.html.
18
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understanding of genetics and biology varies considerably in the general population and
there are people with an incredibly limited knowledge of these topics. Illiterate patients pose
a standard problem for researchers looking to obtain informed consent and must rely on the
practitioners to adequately get information across to these patients. It may also be impossible
to fully inform patients in a philosophical sense where a patient cannot fully understand the
process but this extreme notion is merely speculation. Patients benefit more from having
knowledge available to them and those conducting research are ethically responsible for
attempting to fully inform patients. While patients may not have the necessary experience to
use the data themselves, there are experts in the field of genetics and medical clinics devoted
to the interpretation of genomic information.19 Genetic counselors are specialists devoted to
the interpretation genomic data and clinical care of afflicted patients. Patients should be told
of how to approach further genetic testing if they so desire from either the research consent
forms or the clinicians. One targeted genetic test is not comprehensive, even with the
inclusion of a secondary findings report. Because these reports are only the shallowest probe
into problematic mutations, they should not be the end all for genetic testing which is why
patients should be presented with options where they can bring the information they
received from the initial genetic test.
Patients have different priorities and perspectives when they seek genetic counseling.
One of the oft cited concerns of patients is privacy with regards to their genomic

19
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information.20 One aspect of informed consent is about being within legal boundaries and
knowing laws that affect patients and researchers. Current cultural movements have
emphasized privacy and genetic data is known to be an identifier concerning some patients.
In 1983, the US President’s Commission for the Study of Ethical Problems in Medicine and
Biomedical and Behavioral Research prioritized confidentiality of genetic data over that of
autonomy.21 While NGS technologies have made it much easier for more people to be
sequenced in recent years, the subject of ownership of genetic data and privacy has only
been touched upon by the United States Federal government. In May 2008, the United States
legislative branch passed the Genetic Information Nondiscrimination Act (GINA) guided by
the Office for Human Research Protections and the Department of Health and Human
Services. GINA prohibits discrimination of an individual in health insurance and
employment based on genetic information.22 Health insurers are restricted from requiring
genetic information from an individual or their family as well as restricts using genetic
information for coverage or policies. Employers are also restricted in the same manner where
they are prohibited from requiring genetic information in all aspects of employment and may
not terminate, hire, or influence promotions based on genetic information.
One area that is heavily influenced by GINA are the reporting of secondary findings.
Clearly health insurance companies have a lot to gain from using genetic information in

20
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making a decision on whether to insure to cover a patient who may be susceptible to
hereditary diseases. Clearly, again, this poses an enormous issue for patients seeking health
insurance and the patient-researcher relationship is the topic of this thesis. One issue in
genetics testing is that mutations in certain genes are not guaranteed to lead to issues. These
variants of uncertain significance are not guaranteed to be problematic so even though a
patient has a mutation in that gene, it may not be deleterious or problematic. The
understanding of deleterious mutations is still far too underdeveloped to be used as a
deciding factor in insurance or employment. Employers may discriminate against employees
or applicants because of their susceptibility to hereditary diseases which could take them out
of workplace earlier than the employer desires. Secondary findings that would affect
insurance or employment would be a huge concern for anybody obtaining genetic testing
and would likely lead to more people rejecting these findings which are important for the
future health of an individual. GINA is praised as being a baseline of protection against
discrimination from genetic testing, however this law does not apply to employers with
fewer than 15 employees, the military, and does not cover long term coverage, life insurance
or disability insurance.23 Knowing the legal situation surrounding genetic information may
be important for patients seeking genetic testing which may discourage them from getting
secondary findings. Using genetic information to discriminate against individuals is
contentious because the current knowledge of genetics is not definite and many connections

23
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need to be described between genes. A mutation of unknown significance found on the
BRCA2 gene may be benign but would still show up in a secondary findings report which a
life insurance company may use as a determining factor in their coverage decision.
From an ethical perspective, discrimination based on genetic information
disadvantages people based purely on what they have inherited. Similarities can be drawn to
the discrimination based on race where both are aspects of a person’s life that they never
controlled. Knowing an individual’s genetic information would be beneficial for the business
practices of insurance companies and employers and there are still some loopholes for
companies to use genetic information against people. Insurance and employment are two
essential commodities in the contemporary United States that would likely be in jeopardy if
GINA were not enacted. While this bill is a step in the right direction, GINA is only
considered a minimum basis for protection of genetic information and many states have their
own laws regarding genetic privacy that research institutes must be aware of.24 More
protections should be given to people based on their genetic information. In the case of
genetic information protection from federal law, all information that is pertinent to the
patient needs to be relayed. Patients will need to have enough information to make an
autonomous decision and should know the exceptions to GINA. Certain exceptions may
apply to a patient and it is up to the patient to decide whether they would like secondary
findings reported; even if it means jeopardizing their chances of insurance or employment

24
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because of current laws. If they are employed by a small business with less than 15 people or
disability insurance important to their livelihood or family, they should be informed that
their genetic information is not guaranteed to be protected under federal law. The costbenefit of reporting secondary findings in that kind of scenario may be too great even if
finding out future problems would be beneficial for them. Federal law is the depth that
institutes like RG can inform the patient of whereas the clinician or genetic counselor will be
more familiar with state laws regarding the privacy of genetic information. The clinician and
researchers both provide an important contribution when it comes to giving the patient
enough information for them to access their situation and make an autonomous decision.
The GINA definition of a genetic test includes analysis of human DNA, RNA,
chromosomes, proteins or metabolites as well as tests detecting mutations, genotyping or
chromosome changes.25 Clearly this applies to genetic testing for hereditary diseases that
patients come to Rare Genomics for. Patients should be informed of the laws that apply to
genetics testing which is different for every state, however this is difficult for national
research institutions. This is best left for clinicians and the genetic counselors who have
direct, face-to-face contact with the patient. At the minimum, it is a responsibility of the
researchers to inform patients of federal laws that apply to their genetic information.
A quick summary of GINA and the exceptions of this law should be discussed with
the patient before genetic sequencing or in a release form; both for informed consent and

25
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providing autonomous choice. In a study done by Simon et al. on disclosing individual
research results (IRR) and informed consent processes, only 10 of a sample of 45 documents
on IRRs and secondary findings included references to GINA.26 If researchers do not
reference the legal protections of a patient within the informed consent process, then
veracity is lost. Veracity is essentially the respect for a patient’s autonomy and a sense of
justice. Researchers have an obligation from their position of power to act in the best
interests of the patients which is bolstered by a sense of veracity. This obligation being
comprehensive, accurate and objective transmission of information to the patient. The
professional also fosters an understanding in the patient and this obligation is only non prima
facie when it conflicts with other obligations that the professional has. Information is prima
facie with patients but this may be complicated if patients are deemed incapable of handling
certain information. The hypothetical situation here would be if anxiety is a serious factor in
fully informing the patients of secondary findings. Presumably patients would desire to hear
the secondary findings report after they have made the autonomous decision to have them
reported with the genetic test, however they may change their mind in the interim period or
prove incapable of handling information. Should researchers find deleterious mutations in
the list of scanned genes that could prove serious, there is an argument to be made for
informing the family but keeping the information from the patient. This choice; possibly
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recommended by researchers, and made by clinicians draws a thin line between
disrespecting autonomy and the principle of beneficence. This is likely a case of an ethics of
care and specification where context is incredibly important in these situations. Another
situation where clinicians should care about context is the difference between express and
tacit consent. Express consent is outright making a decision and tacit consent is consent by a
lack of objection.27 Researchers essentially demand express consent by asking patients to read
and sign release forms and tacit consent should not be an issue for researchers. After
reporting the secondary findings to the clinician is where tacit consent may arise when a
patient may be unsure of reading or hearing about the report themselves.
Informed consent with regards to human genetics research can only be achieved if
the patient has fully understood the information disclosed by consent documents and
clinicians. This is generally used to consent to the research or procedure that is to be done
but the informed position may go both ways. An individual may refuse to participate in
genetic testing based on informed refusal where they understand everything that is to be
done but make the conscience decision to not participate. Informed refusal is not the goal of
researchers trying to inform patients but they must respect the decision made by the patient
based on the principle of autonomy discussed later. Informed refusal does not include the
possibility of false beliefs or misinterpretations. An example of informed refusal with regards
to secondary findings could include a patient who understands what genetic testing can offer
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them but, going back to the exceptions of GINA, values disability insurance that could be
jeopardized by the secondary findings of the test. Patients should not have to fear the
discrimination of insurance companies or employers however there are exceptions under
federal law that may apply in this patient’s situation. Researchers have to respect informed
refusal in secondary findings, even if the patient’s agree to topical genetic testing like looking
for a gene that is correlated to the patient’s phenotype. Related to informed refusal but not as
disheartening is the possibility of patients to waiver the process of informed consent.
Clinicians would get the waivers from the patient’s which relives the clinician of having to
consent as the patient just consents. The patient loses the ability to be informed in this case
but this situation is ethically and legally risky for researchers and clinicians. RG requires
patients to provide their complete medical records and the sequencing files of the patient and
immediate family members so relinquishing informed consent is made harder through
release form processes.28 Adding an option for secondary findings may allow patients to just
sign at the dotted line without understanding the benefits and risks they are taking. Release
forms should try and mediate relinquishing informed consent because it does not benefit the
patient to the degree that an informed decision would. Few approaches respect the autonomy
of the patient so the best approach would include a section reminding the patient to ask
questions they may have regarding secondary findings and include a smaller line for the
initials of the patient. It is a right of the patients to be informed when they decide on tests

28

Institute, Rare Genomics. “Authorization for The Release of Medical Information,” n.d.

25

that affect their future and while it is a right of them to also waiver informed decision
making, it is not recommended for optimal benefit.
The benefits of individual patients extend to the general population when included in
genomic data pools for research use. Data sharing in biobanks is a growing practice by
government, research institutions and clinics with the purpose of advancing research for
personalized and preventative medicine. The National Institutes of Health issued the
Genomic Data Sharing Policy in 2014 which dictates that all genomic data collected for
research funded by the NIH will be collected within a biobank. This allows scientists to use
data that has already been collected and expedite the creation of knowledge.29 Other research
that benefits from biobanks are studies on association between genotypes, socioeconomic
parameters, environmental exposure and phenotypes.30 The express goal of the NIH is to
make genomic data publicly available while also protecting the data and privacy of
individuals. The issue of biobanks is the publicity of data and the unique genetic sequence
that all individuals have. States now employ biobanks with newborns for identification
purposes making total genetic non-disclosure essentially invalid. Patients may have questions
or concerns regarding their identity and privacy if their data is included in a biobank. RG is
not inclined to follow NIH statutes and this problem is less relevant for this institute,
however biobanks are a concern for some patients and researchers. Debates surround
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biobanks and how they could be used against patients or individuals but this is not relevant
to the purpose of this thesis. I will however address the issue in brief. Biobanks are not
something to fear for patients because it is not unlike government social identification and
records. Non-invasive government policies already affect all individuals that are likely to be
associated with the genetic sequencing process. With the express goal of the NIH being the
privacy of the genetic data collected for some research, there is little concern for the abuse of
genetic information.
Research institutions need to make these documents readable and available to
patient’s; providing the options for patients to act autonomously and voluntarily while also
acting ethically and beneficently. The FDA’s regulations on informed consent require that
information presented to the patient should be in language understandable to the patient. No
language should be used where the patient must waive or appear to waive any legal rights or
release the institution from liability in the case of negligence.31 The language of
release/consent forms are very important for all parties involved. The forms must be concise
yet informative and readable which is sometimes difficult when discussing genetics and
medical jargon. While a majority of researchers, research participants and patients desire to
report secondary findings, studies suggest that research participants and patients receive
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more complex information that they can reasonably assimilate and use in decision making.32
The assumption made is based on the reasonable person standard which assumes that
information is disclosed to a hypothetical rational and reasonable person. This is a best case
scenario when informing patients and their families but this cannot be true in all cases.
Sometimes the patient is a non-autonomous individual like a child whose parents or
surrogates do not have the ability to comprehend the ramifications of analysis and secondary
findings and may not be able to read consent forms. Information needs to be tailored to that
individuals needs which is difficult to achieve when institutions like RG are separated from
the patient. The clinician or genetic counselor has the best ability to tailor the information to
the patient so it is recommended that the patient consult their care provider before making
decisions. For the part of the researchers, information given to the patient should be in
language that is understandable to the general population. Simon et al. analyzed the average
grade level readability of language found in reports and forms given to patients and found
that the average grade level found in analysis given to patients ranged from 9-12.33 This is a
fair range for most people with a high school diploma but not everyone who may be a
patient or decision maker has that accomplished. The best thing for research institutions to
do would be making their forms as understandable as possible which can be a difficult feat to
achieve. Because of the difficulty of the language and topic, it would be best if the patient
was to consult their clinician or genetic counselor before making a decision.
32
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Clinicians will often be the ones to consult the patients and disclose the information
provided by the research institutions but there will need to be a combined effort between
the clinicians and researchers in obtaining autonomous consent from patients. The method
for contact and consent of patients for the research institution is in-depth consent forms.
These medical forms are the basis for communication between researchers and patients. The
problem that patients may experience is processing the amount of information given to them
and how to respond to the data. The medical release form for RG that relinquishes the
genetic and medical information to researchers is sent directly to the patient who then sends
the form back to the institute. There is no contact between patients and medical
professionals like clinicians or genetic counselors who could help inform patients about what
they are giving to the institute and what they can expect in requesting secondary findings.
Researchers have a duty to inform patients of what they will be analyzing and what the
patient can expect but there is only so much that communication with a representative and a
three-page form can do in informing patients. It is unreasonable to expect that a patient will
be fully informed with this information, especially when including a secondary findings
request section in the medical release form. If the patient has questions regarding medical
information or secondary findings, they must contact the clinician or counselor themselves
which is a difficult thing to expect a patient to do. In the document, I recommend that
patient’s contact their genetic counselor if they have questions about secondary findings but
this is only a recommendation and leaves a lot to be desired. If at all possible, it is
recommended that the research institution go through genetic counselors or clinicians when
29

giving patients the medical release form. While sending the medical release form directly to
patients via email expedites the process for analysis, the expectation of informed consent is
unrealistic. If there is no change to this process it is still acceptable to send the medical
release and secondary findings request to patients because we have given them the
autonomous choice to be fully informed.

Autonomy
The underlying idea central to the thesis so far is the notion of autonomy. Autonomy
is a large focus of the issue on secondary findings and the respect for patient’s autonomy and
practicality sometimes conflict. Not surprisingly, many ethical issues arise when discussing
autonomy and secondary findings. The patient has overriding authority on the conditions of
their genomic data, but as is oftentimes the case with Rare Genomics patient’s, there is
surrogate decision maker because the patient is unfit to make their own autonomous
decisions. These patients could be infants or children or unable to consent because of their
hereditary or mental illness. The clear ethical standard for researchers is the beneficence of
the patient. The substituted judgement standard, where a surrogate makes decisions on what
the patient “would have made”,34 and the pure autonomy standard, where surrogates respect
the wishes of the formerly autonomous,35 do not usually apply in these situations and tend to
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be sub-par ethical compromises. Researchers need to adopt a best interest standard when it
comes to secondary findings and patients.
Autonomy is described as being a decision free of outside influence and coercion. This
is meant as the patient making a voluntary decision to participate in the research without
acting from another’s influence. The focus is on the decision of the patient rather than the
outside circumstances that influence the decision like finances or personal relationships.
Sometimes this is not the case as described above in the case of children or the mentally ill.
There is occasionally the need for surrogate decision making which is defined as someone
making decisions on behalf of those not capable of making informed decisions.36 Parents are
the surrogate decision makers for children and are expected to act in the best benefit of the
child. Parents also have the autonomous decision of whether or not to include secondary
findings within the test reports. This is sometimes complicated when the decision to act is
based on personal beliefs which are not always in the child’s best interest. The famous
common example of this is the parents of Jehovah’s Witnesses who decline to give their child
a lifesaving blood transfusion because of their beliefs. The issue connected with secondary
findings would be the cost-benefit of getting secondary findings reported. While not as
drastic as a blood transfusion, there is a clear benefit for the future of the child if they were
to know things that could affect them in the years following the initial genetic testing.
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The child itself cannot express consent but may decide that it would like access to the
secondary findings report once they become autonomous individuals. Many issues arise
between the future presumed autonomy of the child, the surrogate authority of the parents,
and reporting of secondary findings. This relationship is complex in that there is the
potential harm of labelling a child as bound to develop problems in the future (e.g. increased
chance of certain cancers) contrasted with the benefit of knowing early enough to possibly
plan or commit to treatment. There is also the need to protect the privacy of the child and
their genetic information.37 The problem is further complicated by the anxiety that parents
may experience at having transferred diseases to their child or discovering non-paternity
through analysis. Solutions to these problems are incredibly contextual and involve
researchers, patients, surrogates and clinicians alike. Should the parents deny reporting of
secondary findings via informed refusal, then that leaves the child at a loss of information
later on in life. If researchers conduct secondary finding reports on children and save them,
the surrogate authority of the parents is challenged and the medical professionals are
responsible for holding the information and getting it to the child when they come of age.
The question lies with what are the child’s right to know with their own genetic
information. The unfortunate reality is that some children will never be capable of
autonomous decisions and in this case, the parents have the overarching authority for
decisions. Fortunately, this is not every case and there are children that have the capability
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to become autonomous even with hereditary disadvantages. In the interest of giving the
child choice in the future, genetic testing institutions should allow these children to receive
their secondary finding reports or offer to reanalyze the data when the child comes of age.
One option is to have a preliminary list of genes to scan and save this secondary findings
report. Another option is to offer to retest the child when they become autonomous. The
latter option is attractive because it provides more time for genetic information technology
and knowledge to grow, providing a more wholesome picture. Variants of unknown
significance may be studied more in depth so researchers will know more about how
mutations affect gene function. This assumes the institute will remain operational for a long
period of time which may not be the case when the child becomes autonomous. Even though
there is a chance of the institute discontinuing operations before the child becomes
autonomous, NGS technologies are making genetic testing cheaper and cheaper.38
Presumably genetic testing will be more affordable in the coming years making the loss of
reanalysis by one institute near inconsequential. Research institutions like RG should offer
reanalysis of secondary findings when the child becomes autonomous. Some companies
already offer this for patients.39 The issue is null provided parents opt for the inclusion of
secondary findings for the child.
Things are further complicated when it is not the parents who are designated the
surrogate authority or the situation is unclear. The spouse, child, family member or maybe
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even a close friend may be the surrogate decision maker for an individual and clinicians
should be careful when accepting decisions from surrogates. Claims about what patients
supposedly want are inherently dubious coming from secondary parties. The relationship to
the patient and the clinician’s opinion should be considered when considering the
qualifications of the surrogates. Researchers are mostly separated from the patients for the
sake of anonymity so the clinician’s viewpoint is an important factor in this case with
decision making. Notions of the rules of surrogate authority and the rules of professional
authority in ethics surround the issue of non-autonomous patients.40 Both of these rules serve
to guide who should serve as a surrogate agent to the patient and when a professional has the
right to override a patient’s decisions if they are harmful or poorly contemplated. A quality
of life standard is usually adopted where a surrogate makes the decisions in the patient’s and
the family’s best interest. The issue here is that the surrogacy dynamic sometimes clashes
with the professional opinion of clinicians or researchers. Researcher’s concerned over the
decision made about the patient have little effect on the decision making regarding
secondary findings. Even given multiple important findings that could affect the patient
adversely, if the patient or surrogate agent declines including these findings through
informed refusal, the researcher must respect the autonomy of these patients. Something a
researcher may do is look for these secondary findings save them in case the patient decides
to revisit the findings later or give them to the patient’s clinician to file away should they
have a moral and ethical defense for doing so.
40
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Patients need only a substantial understanding of affairs for the decision to be
considered autonomous. A patient may act autonomously without exercising their right to
information. A patient who signs the form authorizing secondary findings without reading
the information provided is still qualified to act autonomously but chooses not to do so.41
Examples like this bring up the debate of what autonomous people want vs. what they
should want. For secondary findings, it is easy to assume that the logical patient would want
as much information available to them so they can make the best autonomous choice. This is
not always the case for example, patients may fear learning of other problems they may
experience or may not care to learn any more than they have to. People are attracted to
medicinal clinics because they provide professionals qualified to deal with diagnoses and
disease. People are directed to institutes like RGI because these places offer more information
analyzed by qualified individuals that benefit the patients. Clearly patients wish to be
informed but generally agree to have the medical professionals guide them and make
decisions.42 With this in mind, some patients may ask clinicians to make the decision for
them believing that they are more informed and will make the best decision on their behalf.
Autonomy is a right of the patient and it should not be confused as a duty of the patient for
this puts undue pressure onto patients. Researchers cannot force people to make decisions
they do not want to make. Making patients delegate on every issue when they have made it
clear they wish to delegate that responsibility elsewhere is a clear violation of autonomy.
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While the medical professionals should not push the patients to decide everything, in a
standard clinic there is a clear risk of clinician bias towards certain methods of operation that
may not actually be in the best interest of the patient. In the case of genetics testing and in
order to provide the most information possible to the patient for future use, if a clinician or
researcher is given the choice for the autonomous patient then they should have the
secondary findings reported and stored with the clinician for the patient’s benefit. Having
the information accessible to the patient who may be unsure of how to address secondary
findings at the time or in the future gives the patient the most options to work with. The act
of patients passing on their autonomous decisions to those they view as more qualified
should clearly benefit them and having options gives the patient considerable freedom with
their genetic information. This is in line with the notion of mutual decision making between
the patient and the qualified professional discussed previously. The medical professional has
too much power over information and the patient may not know what they are signing up
for. Researchers and clinicians should advocate for reporting secondary findings to patients
but should remain conscious of the patient’s overarching autonomy.
The approach that is described to benefit the patient with regards to autonomy is
choice. Giving options to patients is the best approach to an informed consent policy
regarding human genetics research and secondary findings. In a study that analyzed the
many informed consent forms around the western world given to patients, it found that
around one third of the documents provided a clause for whom researchers were able to give
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information to regarding the individual research results (IRR) and incidental findings (IF,
also known as secondary findings). The options given were the patient’s doctor, a spouse or
family member and other.43 Documents like this tackle two problems by establishing
autonomy of the patient through choice and giving solutions to where secondary findings
may be sent after analysis. Rather than asking the patient to give a binary answer of whether
they would like to receive secondary findings, they are given the chance to evaluate where
they would like the information retained before testing. Information overload for patients is
a challenge that researchers face when obtaining consent. The diversity of patient’s
knowledge of genetics and biology may lead to issues where an individual does not have the
capability to fully understand what is being asked of them and how to interpret the data.
Oftentimes the mode of presenting risks or consequences to patients has an outcome on their
decisions.44 Rephrasing certain terms like “secondary findings” to things such as “other
findings” may have a large impact on if a patient will consent to the research and if they
would be willing to receive secondary findings. Similarly, expressing probability in numeric
and non-numeric means and the use of analogies also helps the patient as well as opening up
the possibility of more people having a better understanding secondary findings. Using
simplified terms to get across the importance of secondary findings and the research itself is
invaluable in consent forms sent to patients and their families. An example of this would be
providing metaphor examples for patients to better understand genetics jargon. Providing
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examples of how secondary findings have affected people and diagnoses may also provide the
patients with a sense of how genetics testing and these findings are important.

What Should Be Included in a Secondary Findings Report?
Informed consent and autonomy are given ethical values that benefit both the
patients and researchers. Within the chapters on informed consent and autonomy, vague
mentioning of certain aspects of secondary findings reports occurred. An example would the
section on how to dissuade patients from relinquishing informed consent. The purpose of
this chapter is to summarize what and how information should be included within secondary
findings reports with the focus on the inner workings of the Rare Genomics Institute.
In order to discuss the method of presenting secondary findings to patients, RG
operations need to be explained. The Rare Genomics Institute operates as a non-profit
organization designed to help diagnose and research rare diseases around the world. The goal
is to help patients with finding personalized research projects and diagnoses.45 The patient or
the patient’s family contacts RG usually with the guidance of a physician and are then sent
an application and medical release form. Patients are assigned a Patient Advocate who is the
contact between the patient and RG and helps guide them through the exome sequencing
and analysis process. RG then connects the patient with a clinical geneticist who then
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determines the eligibility of sequencing and what tests would be beneficial to have
beforehand. After being approved for testing the results take around 2-6 months to be report
back with between 1/3 and ¼ of patients receiving new diagnoses. After initial testing,
patients who desire further analysis of the raw data are dealt with by the RG Science 2.0
team. The most desired outcome is that a gene is identified that is likely causative of the
patient’s problems and RG recommends possible treatment or research options for the
patient to pursue. Some patients are reluctant to commit to testing for various reasons
including monetary ones. RG helps families crowdfund their sequencing by the
recommended clinical geneticists through posting the story of the patient on their website.46
The process of analysis begins after the director of RG’s Science 2.0 team accepts the case.
The cases are passed to volunteer analysts who complete a report which is then edited by the
director of the team. A case will only be submitted if it has been reviewed by RG’s global
network of experts, the analyst and a Community Manager. Once this has been completed,
the director of the Science 2.0 team edits the final report and sends it to the family.
The argument of this thesis is that a secondary findings report should be included
within the final report given to the patient. Currently RG does not deal with secondary
findings so the list of genes on the report are only the ones that pertain to the phenotype and
medical history of the patient. In order to sign up for genetic testing and analysis of results
through RG, patients must fill out a three-page medical release form which asks for the
46
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complete medical records of the patient and the genetic sequencing files of the patient and
immediate family members. Bolded are the words; TYPE OF INFORMATION REQUESTED
and below the two requested items is a section on patient rights and cancellation notices. The
patient’s rights state that the signatory has the right to revoke or cancel the medical release
authorization at any time in writing. The cancellation notice section relieves RG of the
liability of information being released before the receipt of the written notice for
cancellation.

TYPE OF INFORMATION REQUESTED
Complete medical records of patient
Genetic sequencing files of patient and immediate family members

PATIENT RIGHTS
You have the right to revoke or cancel this authorization, in writing, at any time
CANCELLATION NOTICE
Rare Genomics Institute will not be held responsible for any release of medical information
accomplished before receipt of a written notice cancellation. Revocation takes place from the
date of receipt of written request.

Figure 2: Section of the Rare Genomics Institute’s medical form given for
visualization.47
This small section of the medical release form is an optimal place for the secondary findings
request and subsequent relevant information. It is placed just below what is being requested
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via the medical release form and just above the instructions for release cancellation. The
patient will see both the summary of what they will receive, their rights and what course of
action they may take should they change their mind about genetic testing. The wording for a
section designed to ask whether a patient wants secondary findings to be reported should be
similar to the legal language of the medical release form. As discussed on pages 25, it should
contain two signatory sections so that a patient will be more encouraged to be informed and
not relinquish their right to informed consent. The section itself should have a request for
whether the patient would want a secondary findings report to be included with the results
of the Science 2.0 team’s analysis, as well as instructions for who is to receive the report if
not just the patient. Included under the question with a yes or no checkmark should be a
brief definition of secondary findings, a suggestion to talk to a trusted clinician, and the legal
rights of a patient.
This section should absolutely be separate from the medical release request
information because it is more important that the patient understand that secondary findings
are optional which is why it should include a separate signatory section. Similarly, a short
blurb on the Genetic Information Non-Discrimination Act is included in the section on
“Patient’s Rights” as discussed in the Informed Consent chapter. An example of what the
medical release form should include is written below.
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INFORMATION TO BE RELEASED BY

INFORMATION TO BE RELEASED TO

Organization: Rare Genomic Institute
Address: 2657 Annapolis Road, Suite G #105, Hanover, MD 21076
Contact name: Romina Ortiz
Contact Email: romina.ortiz@raregenomics.org

TYPE OF INFORMATION REQUESTED
Complete medical records of patient
Genetic sequencing files of patient and immediate family members
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*Newly Added Section
Secondary findings are defined as being medical information that is discovered
unintentionally and is unrelated to the condition being tested. These would be diseases that
the patient is susceptible to develop in the future. We recommend you discuss the
implications of these findings with your doctor before agreeing to the secondary findings.
For more information on secondary findings, please visit this website:
(http://bioethics.gov/sites/default/files/Clinician%20Primer%20-%20FINAL.pdf)
Would you like to include a secondary findings report in addition to the analysis report for
the condition being tested?
__ Yes

__ No

If you would like to delegate who should receive these findings, please contact your Patient
Advocate.

PATIENT RIGHTS
You have the right to revoke or cancel this authorization, in writing, at any time
*Newly Added Section
You are protected under federal law by the Genetic Discrimination Non-Discrimination Act
to not be discriminated against because of your genetic data by employment or health
insurance companies. This law does not apply to employers with fewer than 15 employees
nor disability or life insurance policies. Local and State laws vary on added protections; we
recommend you discuss the legal implications of genetic testing with your clinician or
genetic counselor before submitting this form.
CANCELLATION NOTICE
Rare Genomics Institute will not be held responsible for any release of medical information
accomplished before receipt of a written notice cancellation. Revocation takes place from the
date of receipt of written request.
I understand that the information I give is my own submission of medical tests, treatments
and results pertaining to myself, my child, and immediate family.
I hereby consent to the release of the specified information I am giving through the medicalrecords sharing website Patients Know Best and allow you to use it only for research
purposes including sharing de-identified information with external experts and
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phenotype/genotype databases. I understand that such information cannot be released
without my informed consent. I acknowledge I have fully reviewed and understand the
contents of this authorization form. My signature below indicates that I hereby agree to and
authorize the release of patient health information to Rare Genomics Institute.

Instructions for Canceling a Request
You must provide a written request to romina.ortiz@raregenomics.org for
revocation/cancellation of the original record release.
We need to have your complete name, date-of-birth, telephone number (home/work) and
the name of the person/agency that you authorized to receive the medical information.
After receipt of the notice, email confirmation will acknowledge your withdrawal of
authorization.
If you have any questions concerning the cancellation process, email.
romina.ortiz@raregenomics.org

Figure 3: Recommendation for the secondary findings
addition to the medical release form.

There is room for volunteer analysts to add on a secondary findings report from the
test results onto the final report. The time it takes to check a list of around 65 genes would
only be a small part of total time taken for analysis. Providing filters for genes targeted to be
reviewed by analysts are already a part of many databases like Omicia Opal. Adding filters
for secondary findings reports streamlines the process and allows analysts to make the call
over whether a mutation is significant enough to report or not. As discussed earlier, there are
44

concerns over mistakes about the significance of the gene. In the case of these genes, they
tend to be monogenic disorders that have been studied extensively and have been shown to
be pathogenic. With the use of Clinvar, COSMIC and Omicia Opal, these genes have been
determined to be problematic for individuals; without necessarily expressing a clear
phenotype of the disease. Omicia has an indicator of the likelihood of deleteriousness of a
mutation which is a good start to analysis. The genetic information loaded onto Omicia is
analyzed by the database which shows indicators of deleteriousness as well as what kind of
mutation occurred. The template genome comes from the 1000 Genome Project and Omicia
compares the subject’s genome to this collection to determine what has been mutated.
RG’s genetic analysis is not supposed to be the end all with genetic sequencing. One
issue that should be made clear within the language of consent forms is that these secondary
findings are not a final diagnosis. Often mutations within certain genes just increase the
likelihood of developing the disease that has been associated with that gene. RG’s analysis of
genetic data is not entirely comprehensive for there are other problems that can be identified
from the genome that RG does not look for. There is a lot of information to be analyzed from
whole exome sequencing and we do not currently have the capability of determining
everything that is possibly disease causing. Included in this thesis are carrier status genes,
primarily X-linked, that are mutated but do not affect the carrier of the mutated gene. The
reason for reporting these genes is to inform the patient or immediate family members that
they have a possibility of passing on this mutated gene to future offspring which could be
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deleterious. An example of this is Fabry’s disease which is a recessive lysosomal storage
disease that is found on the X chromosome and affects all males with the mutation as well as
affects homozygous and some heterozygous females. Informing patients that they are a
carrier for this disease can affect the future decisions of said patient and may help diagnose
other immediate family members with the same mutation. There are far too many of these
kinds of diseases for one secondary findings report to cover. RGs secondary findings report
would cover some of the most important diseases to date with room for improvement in the
future. For a complete analysis of what parents could pass on to their offspring, they will
need to approach another genetic analysis opportunity. RG is devoted to figuring out the
cause of a patient’s suffering and preventing future cases of the disease through
individualized care and they cannot possibly be the end-all for any genetic disease that a
patient may have.

Content of Secondary Findings Report
The meat of any secondary findings report are the genes that are found to be
significantly mutated and likely deleterious. The following genes come from both the
American College of Medical Genetics and Genomics list of recommended genes and
research of monogenic disorders. This section goes through the ACMG list in alphabetical
order by gene. The end will be genes that I recommend be added to both this list and to
secondary findings reports which are listed as new recommendations. The list is kept short
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because RG testing is not an end-all of genetic testing and there is more to be learned about
certain genes which may be determined to be deleterious.
The table is organized alphabetically by gene and includes the disease that the gene is
associated with, the inheritance pattern, disease type and recommender. The disease is
hopefully explained a little bit by the disease type which is just a basic category or
consequence of having the deleterious gene. The legend shows the acronyms for the
inheritance patterns found on the list. One may refer back to the chapter An Introduction to

Genetic Analysis for more information and a refresher on some of the terms used in the
upcoming section. The table is designed to reflect the inheritance of the disease that is
included on the list with subsequent inheritance (separated by a hyphen) that are in the
same row represent the inheritance of other diseases that the gene is associated with.

Legend
AD = Autosomal Dominant
AR = Autosomal Recessive
Smu = Somatic Mutation
Mu = Multifactorial

Gene
ACTA2
ACTC1
APC
APOB

XL = X-Linked
XLR = X-Linked Recessive
XLD = X-Linked Recessive
? = Unknown Inheritance

Disease
Aortic aneurysm, familial
thoracic 6
Familial hypertrophic
cardiomyopathy 11
Adenomatous polyposis
coli
Familial
hypercholesterolemia

Inheritance

Disease Type

Recommender

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

AD
AD - AR?
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Cancer
Susceptibility
Elevated
Cholesterol

ACMG listed
ACMG listed

Gene

Disease

ATRX

Alpha-Thalassemia/Mental
XLD
Retardation Syndrome

BRCA1
BRCA2

Breast-ovarian cancer,
familial 1
Breast-ovarian cancer,
familial 2

Inheritance

Disease Type
Mental
Retardation Carrier status
Cancer
Susceptibility
Cancer
Susceptibility
Skeletal Muscle
Disorder Volatility to
Anesthesia
Carrier status
Proneness to
Rupture of
Arteries
Progressive
Proximal
muscular
dystrophy
Progressive
Proximal
muscular
dystrophy less
severe

Recommender

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

AD

Connective
Tissue Disease Dominant
Negative

ACMG listed

AD
AD

CACNA1S

Malignant hyperthermia

AD - ?

CFTR

Cystic Fibrosis

AR

COL3A1

Ehlers-Danlos syndrome,
type 4

AD

DMD

Duchenne Muscular
Dystrophy

XLR

DMD

Becker Muscular
Dystrophy

XLR

DSC2

DSG2

DSP

FBN1

Arrhythmogenic right
ventricular
cardiomyopathy, type 11
Arrhythmogenic right
ventricular
cardiomyopathy, type 10
Arrhythmogenic right
ventricular
cardiomyopathy, type 8
Marfan's syndrome
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New Rec.
ACMG listed
ACMG listed

ACMG listed
New Rec.
ACMG listed

New Rec.

New Rec.

Gene

Disease

Inheritance

FMR1

Fragile X syndrome

XLD

GLA

Fabry's disease

XL

HTT

Huntington’s Disease

AD

IKBKG
KCNH2

Mucopolysaccharidosis
type II
Incontinentia Pigmenti
Long QT syndrome 2

KCNQ1

Long QT syndrome 1

AD - AR?

KRAS

Leukemia, acute myeloid

AD

IDS

LDLR
LMNA
MEN1

Familial
hypercholesterolemia
Dilated cardiomyopathy
1A
Multiple endocrine
neoplasia, type 1

XLR
XLD
AD

AD
AD - AR?
AD

MLH1

Lynch syndrome

AD

MSH2

Lynch syndrome

AD - AR?

MSH6

Lynch syndrome

AD

MUTYH

MYH-associated polyposis

SMu

MUTYH

Pilomatrixoma

SMu

MYBPC3
MYBPC3
MYH11

Dilated cardiomyopathy
1A
Familial hypertrophic
cardiomyopathy 4
Aortic aneurysm, familial
thoracic 4

Disease Type
Mental
Retardation Carrier status
Heart Disease
and Renal
Failure
Progressive
Neuronal
Degeneration
Progressive
Degeneration
Carrier status
Heart Disease

Recommender

Heart Disease
Cancer
Susceptibility
Elevated
Cholesterol

ACMG listed

Heart Disease

ACMG listed

Cancer
Susceptibility
Cancer
Susceptibility
Cancer
Susceptibility
Cancer
Susceptibility
Cancer
Susceptibility
Cancer
Susceptibility

New Rec.

ACMG listed

New Rec.
New Rec.
New Rec.
ACMG listed

New Rec.
ACMG listed

ACMG listed
ACMG listed
ACMG listed
ACMG listed
ACMG listed
ACMG listed

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed
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Gene
MYH7
MYL2
MYL3
MYLK

Disease
Familial hypertrophic
cardiomyopathy 1
Familial hypertrophic
cardiomyopathy 10
Familial hypertrophic
cardiomyopathy 8
Aortic aneurysm, familial
thoracic 7

Inheritance

Disease Type

Recommender

AD

Heart Disease

ACMG listed

?

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

NDP

Norrie Disease

XLR

NF2

Neurofibromatosis, type 2

AD

OTC
PCSK9
PKP2

Ornithine
transcarbamylase
deficiency
Hypercholesterolemia,
autosomal dominant, 3
Arrhythmogenic right
ventricular
cardiomyopathy, type 9

Degenerative
Blindness and
Mental
Capacities
Cancer
Susceptibility

New Rec.

ACMG listed

XLR

Metabolic
Disorder

New Rec.

AD

Elevated
Cholesterol

ACMG listed

AD

Heart Disease

ACMG listed

PMS2

Lynch syndrome

?

Cancer
Susceptibility

ACMG listed

PRKAG2

Familial hypertrophic
cardiomyopathy 6

AD

Heart Disease

ACMG listed

PRNP

Gerstmann-Straussler
Disease

AD

PTEN

PTEN hamartoma tumor
syndrome

AD - AR?

RB1

Retinoblastoma

SMu - AD?

RET
RET
RET

Familial medullary thyroid
carcinoma
Multiple endocrine
neoplasia, type 2a
Multiple endocrine
neoplasia, type 2b

AD
AD
AD
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Prion Caused
Progressive
Degeneration
Cancer
Susceptibility
Occular
Degeneration
Cancer
Susceptibility
Cancer
Susceptibility
Cancer
Susceptibility

New Rec.
ACMG listed
ACMG listed
ACMG listed
ACMG listed
ACMG listed

Gene

Disease

Inheritance

Disease Type
Skeletal Muscle
Disorder Volitility to
Anestesia

Recommender

RYR1

Malignant hyperthermia

AD - AR?

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

Heart Disease
Cancer
Susceptibility
Cancer
Susceptibility
Cancer
Susceptibility
Cancer
Susceptibility

ACMG listed

AD

Heart Disease

ACMG listed

XLR

Muscular
Degeneration

New Rec.

AD - SMu,
Mu?

Cancer
Susceptibility

ACMG listed

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

AD

Connective
Tissue Disease

ACMG listed

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

AD

Heart Disease

ACMG listed

AD - AR?

Heart Disease

ACMG listed

SCN5A

Catecholaminergic
polymorphic ventricular
tachycardia
Brugada syndrome 1

SCN5A

Long QT syndrome 3

AD

SDHAF2

Paragangliomas 2

AD

SDHB

Paragangliomas 4

AD - ?

SDHC

Paragangliomas 3

AD - ?

SDHD

Paragangliomas 1

AD - AR?

RYR2

SMAD3
SMAX1
STK11
TGFBR1
TGFBR1
TGFBR1
TGFBR2
TGFBR2
TMEM43
TNNI3

Loeys-Dietz syndrome
type 3
Spinal and bulbar
muscular atrophy
Peutz-Jeghers syndrome
Loeys-Dietz syndrome
type 1A
Loeys-Dietz syndrome
type 2A
Marfan's syndrome
Loeys-Dietz syndrome
type 1B
Loeys-Dietz syndrome
type 2B
Arrhythmogenic right
ventricular
cardiomyopathy, type 5
Familial hypertrophic
cardiomyopathy 7
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ACMG listed

ACMG listed
ACMG listed
ACMG listed
ACMG listed

Gene
TNNT2

Disease
Left ventricular
noncompaction 6

Inheritance

Disease Type

Recommender

AD

Heart Disease

ACMG listed

TP53

Li-Fraumeni syndrome 1

AD - AR,
SMu?

Cancer
Susceptibility

ACMG listed

TPM1

Familial hypertrophic
cardiomyopathy 3

AD

Heart Disease

ACMG listed

TSC1

Tuberous sclerosis 1

AD - ?

TSC2

Tuberous sclerosis 2

AD

VHL

Von Hippel-Lindau
syndrome

AD - AR?

WAS

Wiskott-Aldrich
Syndrome

XLR

WT1

Wilms' tumor

SMu - AD,
AR?

Cancer
Susceptibility
Cancer
Susceptibility
Cancer
Susceptibility
Autoimmune
Deficiency Carrier status
Cancer
Susceptibility

ACMG listed
ACMG listed
ACMG listed
New Rec.

ACMG listed

Similar characteristics found on this list are disease type and mode of inheritance. A
lot of the genes recommended are associated with heart disease or cancer susceptibility. This
pattern is representative of the severity of diseases that these genes cause. Heart diseases and
cancer are highly lethal even with today’s modern medical practices. One common trait that
almost all of these genes share is that they do not display symptoms until later in life.
Diseases like Familial hypertrophic cardiomyopathy and Familial medullary thyroid
carcinoma do not present symptoms until 40 or 50 years into life, and one of these symptoms
is sudden death. All of these genes are included because the patient may not know that they
are susceptible to these diseases at the time of genetic testing. Many of these diseases show
autosomal dominant inheritance meaning people have a roughly 50% chance of obtaining
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the mutated and problem causing gene from their affected parents. The severity of the
disease and the mode of inheritance are also primary factors in what is included on this list,
for both the ACMG recommended genes and the new recommendations. Some of the genes
listed were included primarily for carrier status where an affected individual does not display
symptoms of the disease but have a high likelihood of passing a severe disease to offspring.
The reasoning behind including these genes is very similar but the genes themselves have
different effects on the body. Each gene listed can cause this disease if mutated by itself. One
example of a disease that has a multitude of genes associated with it is Arrhythmogenic right
ventricular cardiomyopathy (ARVC). This disease is an example of a severe heart disease and
is not unlike the other heart conditions that have been known to cause sudden death.
Arrhythmogenic right ventricular cardiomyopathy is a disease where fatty tissues
replace cardiomyocytes in the right or both ventricles of the heart and symptoms include
cardiac irregularities, syncope and sudden death. Multiple genes are correlated to this disease
leading to different types or variants that each gene is causative of. The five known genes
responsible for ARVC are TMEM43, DSP, PKP2, DSG2, DSC2. The TMEM43 gene is
responsible for ARVC type 5 and is a response element for an adipogenic transcription factor.
A loss of function in this gene is suggestive of how fibrofatty replacement occurs within the
heart.48 DSP causes ARVC type 8 and has been found connected to other diseases like
Kertoasis Palmoplantaris Striata II, Wolly Hair, Lethal Acantholytic Epidermolysis Bullosa
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Bengtsson, Luiza, and Henning Otto. “LUMA Interacts with Emerin and Influences Its Distribution at the Inner
Nuclear Membrane.” Journal of Cell Science 4, no. 124 (2007): 538–46. doi:10.1242/jcs.019281.
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and Keratoderma. The DSP protein is a part of the desmosome intermediate filament
complex which connects cells together and is a part of the insoluble core. Homozygous and
heterozygous mutations in this gene are known to cause the diseases listed up above. Some
phenotypes of this disease involve rapid degeneration to heart failure at the age of four.
Many different mutations, both homozygous and heterozygous, have been identified as
causative for severe diseases in the DSP gene and making this an important gene to report to
patients.49 PKP2 is also associated with the desmosome complex as well as participates in
linking cadherins to intermediate filaments. Mutations in this gene cause ARVC type 9 and
patients exhibiting PKP2 mutations show arrhythmia earlier non-PKP2 mutations. PKP2
mutation inheritance is autosomal dominant so one mutated allele has the power to create
the disease in an individual.50 The fourth gene is DSG2, which is associated with ARVC type
10 and is also a part of the desmosome. ARVC caused from this gene is autosomal dominant
and dysfunctional DSG2 proteins have been found from many different types of mutations
within the gene. 51 The last gene is DSC2 which is another gene important to the desmosome
complex and causes ARCV type 11. Studies on zebrafish embryos of DSC2 knockouts showed
DSC2 was crucial in developing normal cardiac tissues and lead to myocardial contractility
defects. Similar to PKP2, this gene has been implicated in other hereditary diseases like

O’Neill, Marla J. F. “DESMOPLAKIN; DSP.” OMIM, 2015. http://www.omim.org/entry/125647?search=DSP
&highlight=dsp.
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palmoplantar keratoderma and woolly hair.52 All of these genes are autosomal dominant and
are causative of a severe disease that causes sudden death in individuals. The severity and
ease of obtaining the disease are indicative of why these five genes should be included in
secondary findings reports.
MYH11, MYLK and ACTA2 are another set of genes that are associated with heart
disease. These genes are associated with familial thoracic aortic aneurysm with dissection
(TAAD) 4, 7, and 6 respectively. This disease is associated with the dilation of the aorta and
has been known to suddenly rupture making this a serious cardiac condition. Symptoms can
show up anywhere from childhood to late adulthood. MYH11 encodes for the smooth
muscle myosin heavy chain and is found all throughout the body. The MYH11 gene is
connected to the CBFB gene which encodes for the CBF-Beta protein. Mutations in this
region of MYH11 and the CBFB gene are associated with acute myeloid leukemia, making
mutations in the MYH11 significant53 and enough to report as a secondary finding. Another
factor in the significance of this disease is that it is heterogeneous, meaning one affected
allele in the individual is enough to cause the disease. ACTA2 encodes for an alpha actin
found in skeletal muscle and constitute a major part of the contractile apparatus54. Both
MYH11 and ACTA2 are a part of the smooth muscle cell contractile unit affecting the aorta,

McKusick, Victor A., and Marla J. F. O’Neill. “DESMOCOLLIN 2; DSC2.” OMIM, 2012.
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Differentiation and Predisposes Mice to Acute Myelomonocytic Leukaemia.” Nature Genetics 23, no. 2
(October 1, 1999): 144–46. doi:10.1038/13776.
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however one study suggested that mutations in either or both of these genes accounted for
only around 20% of all familial TAAD diagnoses. Guo et al. (2007) suggested that other
unknown mutations are significant factors in whether an individual develops familial
TAAD.55 The MYLK gene encodes for myosin light chain kinase which is a key enzyme in
muscle contraction. This gene has also been associated with cases of familial TAAD where
Wang et al. (2010) identified two heterozygous variants that seemed to be causative.56 The
MYLK and MYH11 genes have been known to be heterozygous and correlated with familial
thoracic aortic aneurysms meaning one copy of these mutated genes are causative. The
disease can cause sudden death making these mutations possible significant to a patient and
should be reported. While studies suggest that they account for a low amount familial TAAD
cases, these are still significant enough to inform patients about their chances of developing a
cardiovascular disease. The ignorance of other causes of this disease makes reporting these
genes only likely significant, however beforehand knowledge of susceptibility to familial
TAAD is reason enough to be included in a report. The ACTA2 gene is connected with the
MYH11 encoded protein so it should be reported along with the other two.
One of the most discussed sets of genes that affect a large number of people around
the world are the BRCA1 and BRCA2 genes. These genes are known as tumor suppressors
and play roles in transcription, DNA repair and recombination. The BRCA1 gene is a part of
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a genome surveillance complex and is responsible for around 40% of breast cancers and a
larger percentage of ovarian cancers. The TP53 tumor suppressor gene works with the
BRCA1 gene and mutations in both of these are found in 70%-80% of BRCA1 mutated breast
cancers.57 Having non-functional BRCA1 gene has also been implicated in pancreatic
cancers. The BRCA2 gene is similar and plays a role in completion of cell division and DNA
repair. With breast cancer, a mutated BRCA2 gene also shows connections with early onset
prostate cancer in males.58 Both genes show autosomal dominant inheritance and both have
high rates of cancer making them important to report to patients. These are only a few of the
diseases on the ACMG’s list of secondary findings but they are inclusive of the general
attitude that went into choosing which diseases were included.
Proposed additions to the ACMG list
Rationale. This small set of the listed genes is an example of the reasoning behind
why the ACMG included these genes in their list on secondary findings. The list of experts
that made up the list focused on the severity of the disease, when the symptoms present
themselves and the degree of deleteriousness witnessed in known mutations. All the genes
recommended by the ACMG are included in this list due to these factors. New
recommendations were chosen with these criteria in mind as well as being monogenic.
Included in this list are carrier status genes where the patient or the family has a mutated
McKusick, Victor A., and Ada Hamosh. “BREAST CANCER 1 GENE; BRCA1.” OMIM, 2016.
http://www.omim.org/entry/113705?search=BRCA1&highlight=brca1.
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chromosome that has a high likelihood to passing down and causing disease to future
offspring. The reason for including carrier genes is for providing the patient with useful
information in future planning and save offspring from debilitating diseases. If a patient
knows that they have a 50% chance of passing a Mucopolysaccharidosis type II to a future
male child, this information would hopefully influence their decision making. Inheritance
patterns for these carrier status genes tend to be X-linked or autosomal dominant. Many of
the new genes and diseases that I recommend are X-linked monogenic disorders. In studying
monogenic disorders, a large proportion of them that were not included on the ACMG list
were X chromosome linked. Because the mother is generally the one who passes down a
problematic gene due to females having two X chromosomes, X-linked disorders oftentimes
fit into the category of carrier status genes.
MPS II (IDS) One of these carrier status genes is the is the IDS gene which, when
mutated, causes the disease Mucopolysaccharidosis type II (also known as Hunter syndrome)
which has been mentioned multiple times. Mucopolysaccharidosis type II is a lysomal
storage disorder because inactivation of Iduronate 2-sulfatase. This is the enzyme which the
IDS gene encodes for and leads to a buildup of glycosaminoglycans. These molecules disrupt
regular functions of a cell and lead to the distinct phenotype of Hunter Syndrome.59 The
inheritance of this disease is X-linked recessive and mostly affects males who inherit only
one X chromosome from their mother. The life expectancy of an individual is only around
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10-20 years because of the progressive degeneration of function.60 This is a severe disease and
represents only one monogenic disorder that comes from mutations in the X chromosome.
Thalassemia and Fragile-X (ATRX, FMR1) The ATRX gene is also found on the X
chromosome and is associated with the disease combination alpha thalassemia/mental
retardation syndrome. The ATRX gene encodes for a protein within the helicase family and
is believed to be associated with the regulation of gene expression and sex differentiation.
Male patients show varying degrees of undeveloped sexual organs. Mutations that happen to
truncate the gene and eliminate the C-terminal region tend to come with the genital
defects.61 Many different mutations have been implicated in this disease62 which makes this
gene important to report to patients. While this disease is more likely to affect males, it has
been known to affect females because of X-chromosome inactivation where one X
chromosome copy is inactivated in order to prevent overexpression. The importance of
reporting this gene lies with the carrier status of a mutant allele. Fragile X syndrome is a very
similar disease that is also X-linked caused by mutations in the FMR1 gene. This syndrome’s
phenotype is moderate to high mental disabilities and patients tend to exhibit autistic
behavior. FMR1 encodes for a protein thought to be involved in translation and is involved
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in neuron and hippocampus development63. Like alpha thalassemia/mental retardation
syndrome, this disease primarily affects males because of their singular copy of the X
chromosome but can also affect females. Also like the afore mentioned disease, it is
important to inform patients if they are carrying a mutated copy of the gene. Reporting
carrier status to a patient or their family may be an important piece of information if they are
considering having a child. Mental handicaps are a serious issue for some people and the
burden may be more than people are willing to risk. Preimplantation genetic diagnosis is
already an established practice for in-vitro fertilization where genetic tests are run on the
embryo which test for specific diseases or conditions.64 PGD is representative of the
acceptance for scanning a fetus for conditions that would make life hard on the parents. This
issue is seen in a few more new recommendations found on the list.
Duchene and Becker Muscular Dystrophy (DMD) The DMD gene is associated with
two related diseases, Duchenne Muscular Dystrophy and Becker Muscular Dystrophy. Both
diseases involve progress muscle loss and resulting weakness with Becker muscular
dystrophy being the milder form. DMD encodes for dystrophin which is believed to help
actin maintain its bonds while under bending stress. Many different types of mutations have
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been recorded to cause both of these diseases65 which may not appear until later in life.
While this disease may not necessarily be life threatening (Duchenne muscular dystrophy
has been known to shorten life expectancy), it has a major effect on the life of individuals.
The loss of muscle over time affects patients negatively and it is best to inform patients of
what they may experience in the future.
IP and Norrie Disease (IKBKG, NDP) Incontinentia Pigmenti (IP) is an X-linked
dominant disease that primarily affects the skin where the skin is inconsistently pigmented
with sporadic blisters and rashes. It has also been known to influence abnormally developed
eyes and intellectual disability. Symptoms sometimes affect newborns but progressive
elements occur later in life and primarily affects females66. Males with the mutation do not
tend to make it past the embryonic stage of development. The gene responsible is IKBKG
which encodes for a NEMO-like kinase which specifically phosphorylate serine and
threonine that are followed by a proline. Many mutations seem to be deletions within the
gene which cause Incontinentia Pigmenti but this gene is also associated with Ectodermal
dysplasia, hypohidrotic, with immune deficiency which proves to be a serious issue in
affected patients. Affected males show high rates of morbidity and mortality due to recurrent
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infections67. While mutations in this gene are non-lethal for affected females, affected males
have a high mortality rate and patients carrying the mutation should be informed that they
are carriers. A similar disease that affects mental capabilities and blindness is Norrie disease.
The gene associated with Norrie disease is NDP which encodes for norrin which is a cysteine
rich protein associated with the cysteine knot growth factor family.68 Norrie Disease is Xlinked recessive and causes blindness in affected males at birth as well as can lead to
progressive hearing loss and mental handicaps. Like IP, mutations in the NDP gene should be
reported to patients who carry the mutation which in this case are females. Patients will
have more information regarding whether they should have offspring that may be affected
with these diseases so it is important to inform them of mutations in these genes.
Ornithine Transcarbamylase Deficiency (OTC) Ornithine transcarbamylase
deficiency is caused by mutations in the OTC gene which encodes for ornithine
carbamoyltransferase and is involved in the urea cycle of mammals. Deficiency in this
protein leads to increased levels of ammonia in the body which negatively affects the
nervous system. Complications from this gene lead to an umbrella of problems for the patient
from intellectual disability to lethargy to progressive liver damage69. Symptoms usually show
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up at birth but are sometimes not caught until later in life. Males are usually the ones most
affected by this disease but females can also be affected, often through X inactivation70.
Spinal and Bulbar Muscular Atrophy (AR) Similar to Ornithine transcarbamylase
deficiency, Spinal and bulbar muscular atrophy primarily affects males. Symptoms of this
disease include muscle weakness and wasting which occurs in adulthood. The AR gene is
responsible for Spinal and bulbar muscular atrophy and encodes for the androgen receptor
protein involved with androgen response elements. Mutations in AR have also been
associated with Androgen insensitivity syndrome and susceptibility to prostate cancer.
Wiskott-Aldrich syndrome (WAS) The final X-linked disorder is Wiskott-Aldrich
syndrome that is characterized by an abnormal immune system and problems forming blood
clots. WAS is the gene associated with this disease and is involved in Cdc42 signaling.
Patients with Wiskott-Aldrich have a reduced number of platelets in their body and is
caught early on in life because of ease of bleeding and bruising. They also have an increased
chance of developing autoimmune disorders. The only known way to treat this disease is a
bone marrow transplant71.All of these monogenic disorders have severe consequences for
patients, usually males, that inherit mutated genes from their parents. Patients carrying these
diseases should be informed that they have the capacity to pass debilitating or deadly
problems on to their offspring.
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Gerstmann-Straussler disease (PRNP) Non X-linked recommendations that I made
within this list include Gerstmann-Straussler Disease, Cystic Fibrosis, Huntington’s Disease
and acute myeloid Leukemia brought about by KRAS. Gerstmann-Straussler disease is a
prion disease that affects the nervous system and includes ataxia, cognitive dysfunction and
spasticity. Symptoms develop around the ages of 35 to 50 and patients usually live an average
of 5 years after diagnosis72. The PRNP gene is associated with this disease as well as
Creutzfeldt-Jakob disease and a Huntington-like disease. PRNP encodes for a glycoprotein
that is attached to the plasma membrane. The functional form of this protein has a large
alpha-helical structure and the pathogenic isoform in beta-pleated sheets73.
Cystic Fibrosis (CFTR) Cystic Fibrosis is associated primarily with the CFTR gene
which encodes for an ATP-binding cassette and is involved in chloride ion channels.
Characteristics of this disease include buildup of mucus in the lungs and digestive problems.
Symptoms are present from birth and modern medical advancements have allowed patients
with Cystic Fibrosis to live into adulthood74. The severity of the disease is likely influenced
by the presence of mutations in other genes.
Huntington’s Disease (HTT) Another severe disease that develops well into adulthood
is Huntington’s disease which is brought about by mutations in the HTT gene. HTT encodes
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for huntingtin which is a nuclear protein that regulates transcription factors. There is a CAG
repeat that is often found within Huntington’s patients and the disease seems to have a gainof-function aspect to it where the encoded mRNA or resulting protein have a new property
or express inappropriately.75 Symptoms of this disease include loss of motor function,
emotional capabilities and intellectual abilities; and eventually leads to death. This disease is
autosomal dominant so it is likely that a patient whose parent is a carrier of the disease has a
50% chance of obtaining the mutated carrier gene.76
Acute Myeloid Leukemia (KRAS) The last gene recommended was KRAS in
association with acute myeloid Leukemia. Mutations in KRAS are associated with many
different types of cancers so this gene increases cancer susceptibility. This type of leukemia is
adult onset and causes bone marrow to produce abnormal myoblasts. KRAS encodes for a
protein involved in tissue signaling and play a role in proliferation, differentiation and
senescence. Mutated forms of KRAS are prolific oncogenes that have been associated bladder,
breast, gastric and lung cancers as well as Noonan syndrome and acute myeloid leukemia.
The inheritance pattern for acute myeloid leukemia is known to be autosomal dominant
while for other cancers the inheritance in not known. The severity of all of these diseases
and the fact that they are adult-onset or can be are reason to include mutations of these
genes in secondary findings reports.
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Conclusion
The goal of this thesis is to convince institutions, and especially the Rare Genomics
Institute, to implement policies of providing patients with reports on secondary findings. In
having the ability to easily provide more information to patients but neglecting to do so,
institutions and medical professionals are doing a disservice to their patients. We are morally
obligated to act in the greatest beneficent capacity that we can as medical professionals.
Giving patients as much knowledge about their own body as possible is acting in the most
beneficent way because patients have the autonomy to do what they will with that
information. Secondary findings should be encouraged and offered to all patients who
undergo genetic testing. Information is power and patients gain more power over their
situation when they know what they can experience. Federal laws like the Genetic
Information Nondiscrimination Act is at the lowest limit of what is acceptable protection for
individuals. Further protections for patients are needed but the information that is gathered
from secondary findings reports are invaluable just the same.
The general consensus amongst the literature is that secondary findings should be
reported and part of this report uses RG as an example of how to approach the issue with
patients. Because RG does not currently deal with secondary findings it may be a rough
transition to beginning to offer them. Cases that are currently being worked on would likely
receive secondary findings later than their analysis report but even these liminal state cases
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should be offered secondary findings. Cases that have already been closed should also be
offered reanalysis of their genetic data because oftentimes the institution still has the data
and the contact information of the patient. The speed of transition could affect whether some
patients are offered the secondary findings report in a timely manner. Filters in databases or
during sequencing will speed up the process tremendously and there are already some filters
for the ACMG list like in Omicia Opal.
More problematic genes can be expected to show up on this list of secondary findings
from the work that’s being done on monogenic disorders around the world. Reported genes
may expand to well understood polygenic disorders within the next few decades and the role
of unknown elements like introns could be determined and included. I hope to continue
research that contributes to the understanding of hereditary diseases. There is much more
work to be done before finalizing the list of what should be given to patients. The factors of
time, cost and availability of genetic sequencing contribute to the growth and use of genetic
data in diagnosing diseases in contemporary medical practices. The future of genetic analysis
is looking promising and institutions like Rare Genomics need to be using this technology to
their best ability and providing secondary findings to patients to fulfill their express purpose
of helping those in need.
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